New mouse model for study of Creutzfeldt-Jakob disease

Italian researchers have bred mice that exhibit similar deficits to those experienced by people with Creutzfeldt-Jakob disease, a prion disease similar to bovine spongiform encephalopathy. The EU-funded study, published in the journal Neuron, provides insights that may help to diagnose prion diseases early, when therapeutic intervention may be effective.

Creutzfeldt-Jakob disease (CJD) is a degenerative brain disease caused by prions, infectious agents that are made of misfolded proteins (the correct folding of a protein is essential for its function). In CJD, prions cause normal proteins to refold into a diseased state. This happens slowly at first, but normal proteins in the brain are converted at an ever-increasing rate, in a kind of feedback loop. The diseased proteins disrupt normal cell functioning and ultimately cause cell death, creating 'holes' in the tissue.

CJD is always fatal, and infects approximately one in a million people a year worldwide. Prion diseases affect many different species, as the prion protein is similar in all mammals. Bovine spongiform encephalopathy ('mad cow disease') is perhaps the best known of these.

One of the problems prion researchers face when using animal models to study CJD is that prion diseases in humans have a more complex range of clinical signs than can be seen in mice. Humans experience dementia and other disturbances that don't affect movement, whereas in mice only motor dysfunctions, which occur at a late stage of the disease, have been seen.

In the current study, researchers looked at a prion protein mutation (named D178N/V129) that is associated with a kind of CJD in which patients suffer memory deterioration, behavioural changes and motor abnormalities. The only mouse models available were of mice bred with an inherited form of CJD, and these mice did not show any of the same cognitive impairments suffered by their human counterparts.

Dr Roberto Chiesa of the Mario Negri Institute for Pharmacological Research in Italy explained, "We need experimental models with a broader spectrum of clinical signs for insight into the mechanisms of neuronal dysfunction and its evolution, and to identify earlier markers of clinical disease when therapeutic intervention may be effective."

The scientists were able to permanently transfer the relevant defective gene into a mouse's genetic material, such that the mouse expressed its own version of the D178N/V129 mutation. The result was an animal that exhibited similar symptoms to human CJD patients. The animals, called Tg(CJD) mice, show memory impairment and neurophysiologic deficits, including electroencephalography (EEG) abnormalities and sleep alterations, similar to those experienced by a CJD patient with the same mutation.

The researchers also observed other biological abnormalities in the Tg(CJD) mice that suggest that alterations in the endoplasmic reticulum (a part of the cell responsible for protein folding) might contribute to CJD pathology.

"Our results establish the first animal model of a genetic prion disease recapitulating cognitive, motor, and neurophysiological abnormalities of the human disorder," explained Dr Chiesa. "This new model allows in-depth analysis of the disease mechanisms and may be useful for testing potential therapies for inherited prion diseases."

The study was financed in part by the NeuroPrion network ('Prevention, control and management of prion diseases') under the EU's Fifth and Sixth Framework Programmes (FP5 and FP6). NeuroPrion is a five-year project ending in December this year that received EUR 14.4 million in funding to coordinate research efforts on prion diseases in order to ensure protection of human and animal health and to avoid harmful economic consequences.

For more information, please visit:
Neuron, http://www.cell.com/neuron/
Mario Negri Institute for Pharmacological Research, http://www.marionegri.it

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...